# Revealing Putative Causal Genes by Establishing the Causality Between Different Lymphomas and Immune Cells

## TL;DR

This study explores how immune cells and genes might influence different types of lymphoma, identifying potential new treatment targets.

## Contribution

The study introduces a novel integration of genetic methods to reveal causal genes and immune cell interactions in lymphoma subtypes.

## Key findings

- SMR and colocalization analyses identified genes linked to immune cells and lymphoma pathogenesis.
- Genetic correlation and MR methods revealed causal relationships between immune cells and lymphoma subtypes.
- Findings suggest new therapeutic candidates and risk predictors for lymphoma treatments.

## Abstract

The tumour immune microenvironment (TIME) is critical for lymphoma progression and therapy resistance, yet causal relationships between specific immune cell types and lymphoma subtypes remain poorly defined. In this study, using bidirectional Mendelian randomization (MR), genetic correlation (LDSC), and expression‐QTL integration (SMR), we systematically evaluated causal relationships and genetic correlation between immune cells and various lymphomas. Additionally, we utilised the Mendelian randomization‐based method of summary data‐based MR (SMR), which incorporated genome‐wide association studies (GWAS) and expression quantitative trait loci (eQTL) data from immune cells to identify genes associated with lymphoma. Furthermore, colocalization analysis and genetic correlation analysis were conducted for further validation of our findings. The two‐sample mendelian randomization approach was employed to identify the immune cell types that exhibit a causal relationship with different lymphomas. Additionally, the genetic correlation between these immune cells and lymphomas was further analysed using the linked disequilibrium score regression method, thereby enhancing the reliability of our findings. The SMR and colocalisation analyses revealed several genes associated with these immune cells, thereby providing additional support for their putative role in the pathogenesis of lymphoma. Our study elucidates the intricate interplay between immune cells by employing genetic methodologies, thus suggesting novel therapeutic candidates that warrant experimental validation and risk predictors in different subtypes of lymphoma treatments.